---
id: eular-rheumatoid-arthritis-2022
title: "EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological DMARDs: 2022 Update"
short_title: "EULAR Rheumatoid Arthritis 2022"

organization: European Alliance of Associations for Rheumatology
collaborators: null
country: null
url: https://ard.bmj.com/content/82/1/3
doi: 10.1136/ard-2022-223356
pmid: 36357155
open_access: true

specialty: rheumatology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - rheumatoid arthritis
  - inflammatory arthritis
tags:
  - DMARDs
  - biologics
  - JAK inhibitors
  - methotrexate
  - treat-to-target
  - TNF inhibitors

publication_date: 2022-11-10
previous_version_date: 2019-03-06
status: current
supersedes: eular-rheumatoid-arthritis-2019
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Evidence-based recommendations for pharmacological management of rheumatoid arthritis using conventional synthetic, biological, and targeted synthetic DMARDs, including treatment strategies and sequencing.

## Notes

Updates 2019 recommendations. European perspective complementing ACR 2021 guideline. Addresses safety and efficacy of DMARDs and glucocorticoids based on systematic literature review.
